From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?

Since the outbreak of the COVID-19 pandemic in December 2019, the SARS-CoV-2 genome has undergone several mutations. The emergence of such variants has resulted in multiple pandemic waves, contributing to sustaining to date the number of infections, hospitalisations, and deaths despite the swift dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavan, Matteo, Bassani, Davide, Sturlese, Mattia, Moro, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196651/
https://www.ncbi.nlm.nih.gov/pubmed/35695095
http://dx.doi.org/10.1080/14756366.2022.2081847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196651/
https://www.ncbi.nlm.nih.gov/pubmed/35695095
http://dx.doi.org/10.1080/14756366.2022.2081847

Ejemplares similares